Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
|
|
Newsday (12.28.03) - Tuesday, December 30, 2003
Laurie Garrett
Clinton outlined his plan in an article in the New England Journal of Medicine last spring. "Our intention is not to duplicate work but to build on existing plans and to ensure that these plans become operational. Once these plans are in place, I will help to raise the funds needed to implement them," he wrote in "Turning the Tide on the AIDS Pandemic" (2003;348(18):1800-1802).
The foundation started with the Bahamas, offering technical assistance and negotiating lower drug prices. "Because we knew we had these plans we were putting together [in the Caribbean, South Africa, Mozambique, Tanzania and Rwanda]," Magaziner said, "we went to drug companies and said, 'We're ordering for 2 million people.'"
The World Health Organization and Doctors Without Borders have praised the foundation's initiative, saying it has made feasible WHO's global campaign to treat 3 million HIV/AIDS patients by 2005. Current figures estimate that fewer than 800,000 of the 40 million people living with HIV have access to antiretrovirals. Dr. Bernard Pecoul of DWB was particularly pleased by the foundation's success in convincing generic drug manufacturers to combine three HIV medicines into a single, twice-daily pill that costs 36 cents a day.
In July, the foundation sent 24 experts to South Africa to design a $1.5 billion plan to treat roughly 3 million people by 2007. "President Mbeki would never have struck the deal without President Clinton's influence," said Magaziner, "but the deal had to have follow- through." The foundation's success in the Bahamas helped sway Mbeki, according to Magaziner. The foundation is currently negotiating a similar role in China and India.
031230
AD032691
Copyright © 2003 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.